IL17A and inflammatory bowel disease: Elevated IL-17 and IL-23 levels have been demonstrated in patients with SAPHO, particularly during active bone inflammation, and targeted biologics such as ustekinumab, which inhibits the IL-12/23 p40 subunit, as well as IL-17 inhibitors, have shown therapeutic benefit in selected cases of SAPHO-IBD overlap [5-7,28].